红日药业(300026) - 2024 Q1 - 季度财报

Financial Performance - Total operating revenue for the current period is ¥1,463,378,271.09, a decrease of 11.80% compared to ¥1,659,065,577.58 in the same period last year [21]. - Net profit attributable to shareholders for the current period is ¥58,120,874.65, down 66.87% from ¥175,453,588.33 year-on-year [30]. - The total net profit for the current period is 54,398,108.68 CNY, a decrease from 178,792,274.45 CNY in the same period last year [45]. - The total profit for the current period is 76,934,692.86 CNY, down from 214,122,030.01 CNY in the previous year [45]. - The basic earnings per share for the current period is 0.02 CNY, compared to 0.06 CNY in the same period last year [45]. Cash Flow - Net cash flow from operating activities is ¥137,623,131.48, a decline of 61.62% compared to ¥358,569,878.10 in the previous year [30]. - The net cash flow from operating activities for the current period is ¥137,623,131.48, a decrease of 61.6% compared to ¥358,569,878.10 in the previous period [47]. - Cash inflow from operating activities totaled ¥1,503,435,403.84, down 27.5% from ¥2,074,486,190.95 in the previous period [47]. - Cash outflow from operating activities was ¥1,365,812,272.36, a decrease of 20.4% compared to ¥1,715,916,312.85 in the previous period [47]. - The net cash flow from investing activities is -¥48,575,252.14, an improvement from -¥66,327,368.26 in the previous period [47]. - Cash inflow from financing activities was ¥10,694,044.17, significantly lower than ¥160,884,550.78 in the previous period [55]. - Cash outflow from financing activities totaled ¥47,714,483.47, down 85.8% from ¥337,354,295.64 in the previous period [55]. - The net increase in cash and cash equivalents for the current period is ¥51,841,223.34, compared to an increase of ¥112,967,196.84 in the previous period [55]. Assets and Liabilities - Total assets at the end of the current period amount to ¥12,006,356,785.06, reflecting a 1.45% increase from ¥11,835,031,507.96 at the end of the previous year [30]. - The company's total liabilities amount to ¥3,084,618,179.61, an increase from ¥2,967,268,858.43 year-on-year [30]. - The balance of lease liabilities at the end of the period is ¥113,554,295.78, an increase of 91.11% due to new factory leases [33]. - Deferred income tax liabilities increased by 71.65% to ¥39,822,023.92, primarily due to increased lease liabilities [33]. - Total liabilities and equity increased to ¥12,006,356,785.06 from ¥11,835,031,507.96 [51]. Shareholder Information - The number of shares held by the largest shareholder, Chengdu Xingcheng Investment Group Co., Ltd., is 667,997,417, representing 22.24% of the total shares [10]. - The number of shares held by the second-largest shareholder, Yao Xiaoqing, is 307,477,728, representing 10.24% of the total shares [10]. - The company has seen a significant change in shareholder structure, with new shareholders participating in the stock lending program [40]. Other Financial Metrics - Financial expenses for the current period amount to 10.35 million yuan, a decrease of 40.64% compared to the same period last year, mainly due to reduced interest expenses and exchange losses, as well as increased interest income [10]. - Other income for the current period is 1.20 million yuan, a decrease of 92.57% compared to the same period last year, mainly due to a reduction in government subsidies received [10]. - Income tax expenses for the current period amount to 22.54 million yuan, a decrease of 36.21% compared to the same period last year, mainly due to a reduction in deferred income tax expenses [10]. - Research and development expenses for the current period are ¥44,359,218.24, a decrease of 11.93% from ¥49,975,155.97 in the previous year [21]. - The company's weighted average return on equity is 0.67%, down 1.42% from 2.09% in the same period last year [30]. - The company has no non-recurring profit and loss items that meet the definition of non-recurring profit and loss [6]. - The company confirms that the financial information in the quarterly report is true, accurate, and complete [3].